Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Gaw

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Age and Ageing|May 21, 2004
Understanding why older people participate in clinical trials: the experience of the Scottish PROSPER participantsElizabeth P Tolmie, Moira M B Mungall, Greig Louden, et al.
Journal of Clinical Nursing|February 5, 2009
Accuracy of patient recall of preoperative symptom severity (angina and breathlessness) at one year following aorta-coronary artery bypass graftingGrace M Lindsay, Kate A Niven, Eric E Brodie, et al.
BMJ (Clinical Research Ed.)|March 4, 2006
Offering results to research participantsEleanor M Dinnett, Moira M B Mungall, Claire Gordon, et al.
Clinical Trials (London, England)|November 11, 2005
Closing out a large clinical trial: lessons from the prospective study of pravastatin in the elderly at risk (PROSPER)Eleanor M Dinnett, Moira M B Mungall, Jane A Kent, et al.
European Journal of Cardiovascular Nursing|November 19, 2003
Patients' perspectives on statin therapy for treatment of hypercholesterolaemia: a qualitative studyElizabeth P Tolmie, Grace M Lindsay, Susan M Kerr, et al.
The Journal of Family Practice|October 10, 2008
How to reach LDL targets quickly in patients with diabetes or metabolic syndromeLawrence A Leiter, Pierre Martineau, Eduardo de Teresa, et al.
Clinical Trials (London, England)|November 11, 2005
Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Eleanor M Dinnett, Moira M B Mungall, Jane A Kent, et al.
Diabetes|March 31, 2007
Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factorNaveed Sattar, Alex McConnachie, Ian Ford, et al.
Diabetes|April 30, 2002
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention StudyDilys J Freeman, John Norrie, Muriel J Caslake, et al.
American Heart Journal|April 25, 2007
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified TitrationLuis Miguel Blanco-Colio, Jose Luis Martín-Ventura, Eduardo de Teresa, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Age and Ageing|May 21, 2004
Understanding why older people participate in clinical trials: the experience of the Scottish PROSPER participantsElizabeth P Tolmie, Moira M B Mungall, Greig Louden, et al.
Journal of Clinical Nursing|February 5, 2009
Accuracy of patient recall of preoperative symptom severity (angina and breathlessness) at one year following aorta-coronary artery bypass graftingGrace M Lindsay, Kate A Niven, Eric E Brodie, et al.
BMJ (Clinical Research Ed.)|March 4, 2006
Offering results to research participantsEleanor M Dinnett, Moira M B Mungall, Claire Gordon, et al.
Clinical Trials (London, England)|November 11, 2005
Closing out a large clinical trial: lessons from the prospective study of pravastatin in the elderly at risk (PROSPER)Eleanor M Dinnett, Moira M B Mungall, Jane A Kent, et al.
European Journal of Cardiovascular Nursing|November 19, 2003
Patients' perspectives on statin therapy for treatment of hypercholesterolaemia: a qualitative studyElizabeth P Tolmie, Grace M Lindsay, Susan M Kerr, et al.
The Journal of Family Practice|October 10, 2008
How to reach LDL targets quickly in patients with diabetes or metabolic syndromeLawrence A Leiter, Pierre Martineau, Eduardo de Teresa, et al.
Clinical Trials (London, England)|November 11, 2005
Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Eleanor M Dinnett, Moira M B Mungall, Jane A Kent, et al.
Diabetes|March 31, 2007
Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factorNaveed Sattar, Alex McConnachie, Ian Ford, et al.
Diabetes|April 30, 2002
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention StudyDilys J Freeman, John Norrie, Muriel J Caslake, et al.
American Heart Journal|April 25, 2007
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified TitrationLuis Miguel Blanco-Colio, Jose Luis Martín-Ventura, Eduardo de Teresa, et al.
Pageof 5